Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.37 |
| ▸ | SMC2 | O95347 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.37 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039197 | 0.90 | ALDH1A1 (0.41) | RAB9ASMN1; SMN2ALDH1A1HPGDMAP2K1 | |
| SCHEMBL9886074 | 0.90 | MEN1 (0.43) | RAB9ASMN1; SMN2PTGS2MAP2K1TDP1 | |
| SCHEMBL2877121 | 0.90 | PTGS2 (0.43) | RAB9ASMN1; SMN2ALDH1A1PTGS2HPGD | |
| SCHEMBL4546127 | 0.89 | NUDT1 (0.45) | RAB9ASMN1; SMN2ALDH1A1HPGDMAP2K1 | |
| SCHEMBL1040434 | 0.89 | NR4A2 (0.40) | RAB9ASMN1; SMN2ALDH1A1PTGS2HPGD | |
| SCHEMBL9886072 | 0.88 | MAP2K1 (0.55) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL13636440 | 0.88 | ALDH1A1 (0.50) | RAB9ASMN1; SMN2ALDH1A1HPGDMAP2K1 | |
| Hydrazine SCHEMBL17625883 | 0.87 | ACLY (0.42) | RAB9ASMN1; SMN2ALDH1A1HPGDMAP2K1 | |
| SCHEMBL6016742 | 0.87 | ACLY (0.44) | RAB9ASMN1; SMN2ALDH1A1HPGDMAP2K1 | |
| SCHEMBL4546025 | 0.86 | PTGS2 (0.48) | RAB9ASMN1; SMN2ALDH1A1PTGS2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3000810-B1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | ARRAY BIOPHARMA INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-3000810-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | Array Biopharma, Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2275102-B1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8513293-B2 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8193230-B2 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193230-B2 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193229-B2 | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8178693-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178693-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8003805-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7425637-B2 | mitogen-activated protein/extracellular signal-regulated (MAP/ERK)Kinase pathways; 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide; hyperproliferative diseases; anticarcinogenic and antiinflammatory agent | ARRAY BIOPHARMA INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425637-B2 | mitogen-activated protein/extracellular signal-regulated (MAP/ERK)Kinase pathways; 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide; hyperproliferative diseases; anticarcinogenic and antiinflammatory agent | ARRAY BIOPHARMA INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080177082-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080177082-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080171778-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080171778-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171778-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | RAB9A 356/4885SMN1; SMN2 3319/4885ALDH1A1 1438/4885 |
| US-20080177082-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | RAB9A 356/4885SMN1; SMN2 3319/4885ALDH1A1 1438/4885 |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | RAB9A 278/4885SMN1; SMN2 3546/4885ALDH1A1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.